Disparities in Allogeneic Hematopoietic Stem Cell Transplantation Among Acute Myeloid Leukemia Patients.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Acute myeloid leukemia (AML) is the most prevalent form of leukemia. Allogeneic hematopoietic cell transplantation (Allo-HCT) is the most effective treatment for most AML subtypes and remains the only curative option for many patients. However, it is recognized that many eligible patients who could benefit from Allo-HCT do not receive this treatment, particularly African American patients. With recent advancements in donor availability, we aimed to examine whether demographic, socioeconomic status and healthcare access disparities in first-course Allo-HCT utilization have decreased over time. Data on patients diagnosed with AML between 2004 and 2019 were obtained from the National Cancer Database (N = 85,787). Adjusted linear regression models were utilized to calculate annual absolute changes (AACs) and corresponding 95% confidence intervals (CIs) across levels of previously identified significant variables to quantify trends in Allo-HCT disparities over time. Among the 85,787 patients diagnosed with AML from 2004 to 2019, non-Hispanic Black patients, those with Medicare, individuals residing in areas with lower ZIP-code-level education and income, and patients reported from community or integrated network cancer programs continuously exhibited the lowest first-course Allo-HCT rates throughout the study period. When quantifying the trends, non-Hispanic Black patients (AAC = -0.18%; 95% CI: -0.33%, -0.03%), those with Medicaid (AAC = -0.53%; 95% CI: -0.72%, -0.35%), Medicare (AAC = -0.94%; 95% CI: -1.03%, -0.86%), and those reported from community (AAC = -0.40%; 95% CI: -0.49%, -0.31%) and integrated network cancer programs (AAC = -0.06%; 95% CI: -0.17%, 0.06%) had lower AACs for first-course Allo-HCT compared to non-Hispanic White patients, those with private insurance, and those reported from academic/research programs, respectively. Patients in the highest ZIP-code-level education (AAC = 0.20%; 95% CI: 0.07%, 0.32%) and income (AAC = 0.23%; 95% CI: 0.11%, 0.35%) areas had significantly higher first-course Allo-HCT AACs compared to those residing in areas with lower education and income levels, respectively. Despite increased donor availability, subgroups that initially exhibited lower Allo-HCT rates-including racial/ethnic minorities, patients insured through Medicaid or Medicare, patients residing in lower education and income areas, and those reported from community or integrated network cancer programs-continue to demonstrate persistently lower utilization and slower growth in Allo-HCT over time, suggesting worsening of the disparities. Further research is warranted to explore factors contributing to persistent disparities in Allo-HCT utilization among underserved populations.